Questcor Rises On Unusually High Volume (QCOR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Questcor Pharmaceuticals (Nasdaq: QCOR) is trading at unusually high volume Thursday with 11 million shares changing hands. It is currently at 4.3 times its average daily volume and trading up $3.52 (+13.4%) at $29.87 as of 10:25 a.m. ET.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Questcor has a market cap of $3.01 billion and is part of the health care sector and drugs industry. Shares are up 21.5% year to date as of the close of trading on Wednesday.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. The company has a P/E ratio of 24.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Questcor as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Questcor Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Cramer: Reviewing S&P's Hit-and-Miss Parade

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Greenberg on the Stock Market: Why Investigations No Longer Matter

Retrophin CEO Under Fire for Twitter Faux Pas

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today